Nitrated apolipoprotein A-I, a potential new cardiovascular marker, is markedly increased in low high-density lipoprotein cholesterol subjects

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 1, 2009, Pages 60-69

  Bakillah, Ahmed ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Cardiovascular; Enzyme linked immunosorbent assay (ELISA); High density lipoprotein; Myeloperoxidase; Nitrotyrosine

Indexed keywords

3 NITROTYROSINE; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NITRATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; WESTERN BLOTTING;

ADULT; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRATES; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 58149242499     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.017     Document Type: Article

References (52)

1. Gaut JP, Byun J, Tran HD, Heinecke JW. Artifact-free quantification of free 3-chlorotyrosine, 3-bromotyrosine, and 3-nitrotyrosine in human plasma by electron capture-negative chemical ionization gas chromatography mass spectrometry and liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Biochem 2002;300:252-9.
2. Duzguncinar O, Yavuz B, Hazirolan T, Deniz A, Tokgozoglu SL, Akata D, et al. Plasma myeloperoxidase is related to the severity of coronary artery disease. Acta Cardiol 2008;63:147-52.
3. Sun YC, Chang PY, Tsao KC, Wu TL, Sun CF, Wu LL, et al. Establishment of a sandwich ELISA using commercial antibody for plasma or serum 3-nitrotyrosine (3NT). Elevation in inflammatory diseases and complementary between 3NT and myeloperoxidase. Clin Chim Acta 2007;378:175-80.
4. Shimizu K, Ogawa F, Muroi E, Hara T, Komura K, Bae SJ, et al. Increased serum levels of nitrotyrosine, a marker for peroxynitrite production, in systemic sclerosis. Clin Exp Rheumatol 2007;25:281-6.
5. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 2006;111:16-26.
6. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. J Am Med Assoc 2003;289:1675-80.
7. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 2004;279:42977-83.
8. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, Thompson JA. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 1996;93:11853-8.
9. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 1998;37:1613-22.
10. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-41.
11. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 2004;101:13032-7.
12. Van Der Vliet A, Nguyen MN, Shigenaga MK, Eiserich JP, Marelich GP, Cross CE. Myeloperoxidase and protein oxidation in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2000;279:L537-46.
13. Hickman-Davis JM, Lindsey JR, Matalon S. Cyclophosphamide decreases nitrotyrosine formation and inhibits nitric oxide production by alveolar macrophages in mycoplasmosis. Infect Immun 2001;69:6401-10.
14. Baldus S, Eiserich JP, Brennan ML, Jackson RM, Alexander CB, Freeman BA. Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radic Biol Med 2002;33:1010.
15. Exner M, Minar E, Mlekusch W, Sabeti S, Amighi J, Lalouschek W, et al. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 2006;47:2212-8.
16. Bergt C, Nakano T, Ditterich J, DeCarli C, Eiserich JP. Oxidized plasma high-density lipoprotein is decreased in Alzheimer's disease. Free Radic Biol Med 2006;41:1542-7.
17. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, et al. Potential clinical utility of high-density lipoprotein-mimetic peptides. Curr Opin Lipidol 2006;17:440-4.
18. Shao B, Bergt C, Fu X, Green P, Voss JC, Oda MN, et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem 2005;280:5983-93.
19. Shao B, Heinecke JW. Using tandem mass spectrometry to quantify site-specific chlorination and nitration of proteins: model system studies with high-density lipoprotein oxidized by myeloperoxidase. Methods Enzymol 2008;440:33-63.
20. Hussain MM, Zhao Y, Kancha RK, Blackhart BD, Yao Z. Characterization of recombinant human apoB-48-containing lipoproteins in rat hepatoma McA-RH7777 cells transfected with apoB-48 cDNA. Overexpression of apoB-48 decreases synthesis of endogenous apoB-100. Arterioscler Thromb Vasc Biol 1995;15:485-94.
21. Bakillah A, Zhou Z, Luchoomun J, Hussain MM. Measurement of apolipoprotein B in various cell lines: correlation between intracellular levels and rates of secretion. Lipids 1997;32:1113-8.
22. Luchoomun J, Zhou Z, Bakillah A, Jamil H, Hussain MM. Assembly and secretion of VLDL in nondifferentiated Caco-2 cells stably transfected with human recombinant ApoB48 cDNA. Arterioscler Thromb Vasc Biol 1997;17:2955-63.
23. Miyazaki O, Kobayashi J, Fukamachi I, Miida T, Bujo H, Saito Y. A new sandwich enzyme immunoassay for measurement of plasma pre-beta1-HDL levels. J Lipid Res 2000;41:2083-8.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
25. Ohshima H, Friesen M, Brouet I, Bartsch H. Nitrotyrosine as a new marker for endogenous nitrosation and nitration of proteins. Food Chem Toxicol 1990;28:647-52.
26. ter Steege JC, Koster-Kamphuis L, van Straaten EA, Forget PP, Buurman WA. Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radic Biol Med 1998;25:953-63.
27. Walsh A, Ito Y, Breslow JL. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J Biol Chem 1989;264:6488-94.
28. Khan J, Brennand DM, Bradley N, Gao B, Bruckdorfer R, Jacobs M. 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J 1998;330(Pt 2):795-801.
29. Hermo R, Mier C, Mazzotta M, Tsuji M, Kimura S, Gugliucci A. Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients. Clin Chem Lab Med 2005;43:601-6.
30. Khan F, Ali R. Antibodies against nitric oxide damaged poly L-tyrosine and 3-nitrotyrosine levels in systemic lupus erythematosus. J Biochem Mol Biol 2006;39:189-96.
31. Khan F, Siddiqui AA, Ali R. Measurement and significance of 3-nitrotyrosine in systemic lupus erythematosus. Scand J Immunol 2006;64:507-14.
32. Collet X, Perret B, Simard G, Raffai E, Marcel YL. Differential effects of lecithin and cholesterol on the immunoreactivity and conformation of apolipoprotein A-I in high density lipoproteins. J Biol Chem 1991;266:9145-52.
33. Chiba H, Mitamura T, Matsuno K, Kobayashi K. A sensitive sandwich enzyme-linked immunosorbent assay of rat apolipoprotein A-I: effect of various sample treat ments on apolipoprotein A-I immunoreactivity and an application to young and aged rat sera. Biochem Med Metab Biol 1991;46:380-90.
34. Duncan MW. A review of approaches to the analysis of 3-nitrotyrosine. Amino Acids 2003;25:351-61.
35. Qu LN, Yang TB, Yuan YH, Zhong P, Yang B, Zhao H. A novel competitive ELISA for both free and protein-bound nitrotyrosine. Hybrid Hybridom 2003;22:401-6.
36. Shigenaga MK, Lee HH, Blount BC, Christen S, Shigeno ET, Yip H, et al. Inflammation and NO(X)-induced nitration: assay for 3-nitrotyrosine by HPLC with electrochemical detection. Proc Natl Acad Sci USA 1997;94:3211-6.
37. Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 2006;45:676-84.
38. Ferlito S, Gallina M, Catassi S, Bisicchia A, Di Salvo MM. Nitrite plasma levels in normolipemic and hypercholesterolemic patients with peripheral occlusive arteriopathy. Panminerva Med 1999;41:307-9.
39. Vergnani L, Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G, et al. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation 2000;101:1261.
40. Hamdheydari L, Christov A, Ottman T, Hensley K, Grammas P. Oxidized LDLs affect nitric oxide and radical generation in brain endothelial cells. Biochem Biophys Res Commun 2003;311:486-90.
41. Choi JW. Enhanced nitric oxide production is closely associated with serum lipid concentrations in adolescents. Clin Chim Acta 2004;347:151-6.
42. Sviridov D, Chin-Dusting J, Nestel P, Kingwell B, Hoang A, Olchawa B, et al. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport. Transplantation 2006;81:361-6.
43. Kawano M, Nagasaka S, Yagyu H, Ishibashi S. Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb 2008;15:41-6.
44. Chau P, Nakamura Y, Fielding CJ, Fielding PE. Mechanism of prebeta-HDL formation and activation. Biochemistry 2006;45:3981-7.
45. Suzuki M, Wada H, Maeda S, Saito K, Minatoguchi S, Saito K, et al. Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. Clin Chem 2005;51:132-7.
46. Miida T, Inano K, Nakamura Y, Matsuto T, Hoshiyama M, Kaneko K, et al. Abnormality of HDL subfractions in cholesteryl ester transfer protein deficiency. Rinsho Byori 1996;44:865-70.
47. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 2005;46:2246-53.
48. Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 2007;99:681-5.
49. Hirayama S, Miida T, Miyazaki O, Aizawa Y. Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 2007;30:1289-91.
50. Parastatidis I, Thomson L, Fries DM, Moore RE, Tohyama J, Fu X, et al. Increased protein nitration burden in the atherosclerotic lesions and plasma of apolipoprotein A-I deficient mice. Circ Res 2007;101:368-76.
51. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56.
52. Vaisar T, Shao B, Green PS, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase and inflammatory proteins: pathways for generating dysfunctional high-density lipoprotein in humans. Curr Atheroscler Rep 2007;9:417-24.